EQL Pharma Management
Management criteria checks 2/4
EQL Pharma's CEO is Axel Schorling, appointed in Aug 2022, has a tenure of 3.83 years. total yearly compensation is SEK2.90M, comprised of 61% salary and 39% bonuses, including company stock and options. directly owns 0.98% of the company’s shares, worth SEK7.02M. The average tenure of the management team and the board of directors is 0.9 years and 5.9 years respectively.
Key information
Axel Schorling
Chief executive officer
SEK 2.9m
Total compensation
| CEO salary percentage | 61.01% |
| CEO tenure | 3.8yrs |
| CEO ownership | 1.0% |
| Management average tenure | less than a year |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Narrative Update • Jun 17
EQL: European Rollout And New UTI Therapy Will Drive Future Upside
Analysts have kept their SEK price target for EQL Pharma broadly unchanged, with only minimal adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E. This reflects a largely steady view of the stock's valuation profile.Narrative Update • Jun 02
EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside
Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.Analysis Article • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Analysis Article • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...Narrative Update • Apr 23
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.Narrative Update • Apr 09
EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.Narrative Update • Mar 26
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.Narrative Update • Mar 11
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.Narrative Update • Feb 24
EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook
Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.Narrative Update • Feb 10
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.Narrative Update • Jan 27
EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Narrative Update • Jan 12
EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside
Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Narrative Update • Dec 23
EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential
Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.Narrative Update • Dec 09
EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside
Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.Narrative Update • Nov 25
EQL: Expanding Market Approvals And New Launches Will Drive Future Upside
Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.Analysis Article • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Narrative Update • Nov 06
EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.Analysis Article • Oct 08
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysis Article • Sep 27
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Sep 09
Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Narrative Update • Aug 16
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q2 update Solid report. Revenue growth in line with expectations.Analysis Article • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...New Narrative • May 11
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Analysis Article • Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Narrative • Feb 22
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.Analysis Article • Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analysis Article • Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...Analysis Article • Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...Analysis Article • Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...Analysis Article • May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
EQL Pharma AB (publ)'s ( NGM:EQL ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | SEK 13m |
| Dec 31 2025 | n/a | n/a | SEK 29m |
| Sep 30 2025 | n/a | n/a | SEK 30m |
| Jun 30 2025 | n/a | n/a | SEK 43m |
| Mar 31 2025 | SEK 3m | SEK 2m | SEK 43m |
| Dec 31 2024 | n/a | n/a | SEK 35m |
| Sep 30 2024 | n/a | n/a | SEK 31m |
| Jun 30 2024 | n/a | n/a | SEK 26m |
| Mar 31 2024 | SEK 2m | SEK 2m | SEK 23m |
Compensation vs Market: Axel's total compensation ($USD297.01K) is about average for companies of similar size in the Swedish market ($USD306.11K).
Compensation vs Earnings: Axel's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Axel Schorling (40 yo)
3.8yrs
Tenure
SEK 2,903,000
Compensation
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 20.4yrs | SEK 340.00k | no data | |
| President & CEO | 3.8yrs | SEK 2.90m | 0.98% SEK 7.0m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 3.8yrs | no data | 0.21% SEK 1.5m | |
| Head of Accounting | less than a year | no data | 0.046% SEK 331.5k | |
| Chief Sales Officer | less than a year | no data | no data | |
| Chief Business Development Officer | 3.3yrs | no data | 0.20% SEK 1.4m | |
| CQSCO & Supply Chain Officer | 1.4yrs | no data | no data | |
| Chief Quality | less than a year | no data | no data |
0.9yrs
Average Tenure
45yo
Average Age
Experienced Management: EQL's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 20.4yrs | SEK 340.00k | no data | |
| Independent Director | 6.4yrs | SEK 180.00k | 0.0085% SEK 60.4k | |
| Independent Director | 7.8yrs | SEK 200.00k | 0.034% SEK 241.5k | |
| Independent Director | 5.4yrs | SEK 170.00k | 0.034% SEK 241.5k | |
| Director | 1.8yrs | SEK 150.00k | no data | |
| Independent Director | less than a year | no data | no data |
5.9yrs
Average Tenure
59yo
Average Age
Experienced Board: EQL's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 11:56 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EQL Pharma AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |